Inventory

The major classes of inventory were as follows:



Inventory	June 30, 2015		December 31, 2014
	(in thousands)
Raw materials	$	35,712	$	40,533
Work-in-progress	77,150		34,095
Finished goods	14,917		6,822
Total	$	127,779	$	81,450

The Company reviews inventory, including inventory purchase commitments, for slow moving or obsolete amounts based on expected volume and provides reserves against the carrying amount of inventory as appropriate. During the three-month period ended June 30, 2015 upon review of expected future Angiomax volumes, the Company recorded a $7.6 million inventory obsolescence charge due primarily to the loss of market exclusivity for Angiomax in the United States.